代利霞,涂小琼,蔡冰冰.达沙替尼治疗不同临床分期慢性粒细胞白血病患者的临床研究[J].肿瘤学杂志,2018,24(10):997-1001.
达沙替尼治疗不同临床分期慢性粒细胞白血病患者的临床研究
Clinical Efficacy of Dasatinib in the Treatment of Different Stages of Chronic Myelogenous Leukemia
投稿时间:2017-06-12  
DOI:10.11735/j.issn.1671-170X.2018.10.B012
中文关键词:  慢性粒细胞白血病  达沙替尼  慢性期  加速期  急变期  临床疗效
英文关键词:chronic myeloid leukemia  dasatinib  chronic phase  accelerated phase  blast crisis  clinical efficacy
基金项目:
作者单位
代利霞 湖北医药学院附属随州医院 
涂小琼 湖北医药学院附属随州医院 
蔡冰冰 湖北医药学院附属随州医院 
摘要点击次数: 1748
全文下载次数: 486
中文摘要:
      摘 要:[目的] 探讨达沙替尼治疗不同临床分期慢性粒细胞白血病(CML)患者的临床疗效。[方法] 收集接受达沙替尼治疗的CML患者84例,其中慢性期(CP组)51例,加速期(AP组)18例,急变期(BP组)15例。比较3组的缓解情况、药物相关不良反应及生存情况。[结果] CP组的完全血液学缓解(CHR)率、完全细胞遗传学反应(CCR)缓解率及主要分子生物学缓解(MMR)率分别为92.16%、86.27%、78.43%,显著高于AP组的72.22%、61.11%、44.44%和BP组的66.67%、53.33%、40.00%(P均<0.05);CP组的中位总生存(OS)时间、中位无复发生存(RFS)时间均显著长于AP组和BP组(P<0.05);CP组随访期内死亡率为1.96%,显著低于AP组的22.22%和BP组的26.67%(P<0.05);CP组的Ⅲ~Ⅳ级血液学不良反应发生率为13.73%,显著低于AP组的38.89%和BP组的46.67%(P<0.05)。[结论] 达沙替尼治疗CML的疗效显著且安全性好,是治疗慢性期CML的优先治疗选择。
英文摘要:
      Abstract:[Objective] To evaluate the clinical efficacy of dasatinib in the treatment of different stages of chronic myelogenous leukemia(CML). [Methods] Totally 84 patients with CML were enrolled,including 51 in the chronic phase(CP group),18 in the accelerated phase(AP group) and 15 in the blast phase(BP group).The remission,drug-related adverse reactions and survival condition of the three groups were compared. [Results] The complete hematologic response(CHR),complete cytogenetic response(CCR) and major molecular biology remission(MMR) ratesofthe CP group were 92.16%,86.27% and 78.43%,respectively,significantly higher than those of the AP group(72.22%,61.11% and 44.44%,respectively;P<0.05)and theBP group(66.67%,53.33% and 40.00%,respectively;P<0.05).The median overall survival(OS) time and median recurrence-free survival(RFS) time of the CP group were both significantly longer than those of the AP group and the BP group(P<0.05).The death rate in the follow-up period of the CP group(1.96%)was significantly lower than thoseof the AP group(22.22%) and the BP group(26.67%)(P<0.05). The incidence rate of grade Ⅲ/Ⅳhematologic adverse events was 13.73% in the CP group,significantly lower than that of the AP group(38.89%) and the BP group(46.67%)(P<0.05).[Conclusion] Dasatinib is an effective and safe alternative for treating chronic CML.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器